EGRX (Eagle Pharmaceuticals) Other Stockholders Equity: $0.0 Mil (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EGRX Eagle Pharmaceuticals Inc EGRX
16 GF Score
Price $0.75
View Full Analysis

What is Eagle Pharmaceuticals Other Stockholders Equity?

Eagle Pharmaceuticals EGRX 16 Other Stockholders Equity is $0.0 Mil as of Jun. 2023. GuruFocus rates EGRX with a GF Score™ of 16/100.

Eagle Pharmaceuticals's Other Stockholders Equity for the quarter that ended in Jun. 2023 was $0.0 Mil.

Eagle Pharmaceuticals's quarterly Other Stockholders Equity declined from Dec. 2022 ($0.0 Mil) to Mar. 2023 ($0.0 Mil) but then stayed the same from Mar. 2023 ($0.0 Mil) to Jun. 2023 ($0.0 Mil).

Eagle Pharmaceuticals's annual Other Stockholders Equity declined from Dec. 2020 ($0.0 Mil) to Dec. 2021 ($-0.0 Mil) but then increased from Dec. 2021 ($-0.0 Mil) to Dec. 2022 ($0.0 Mil).

Eagle Pharmaceuticals Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Eagle Pharmaceuticals's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eagle Pharmaceuticals Other Stockholders Equity Chart

Eagle Pharmaceuticals Annual Data
Trend Sep13 Sep14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 0.00 0.00 -0.00 0.00

Eagle Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 0.00 0.00 0.00 0.00
EGRX
16GF Score
Eagle Pharmaceuticals Inc EGRX
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eagle Pharmaceuticals Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $0.0 Mil mean?
Eagle Pharmaceuticals (EGRX) has a Other Stockholders Equity of $0.0 Mil as of Jun. 2023. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Eagle Pharmaceuticals and its competitors.
Is Eagle Pharmaceuticals' Other Stockholders Equity too high?
Eagle Pharmaceuticals' current Other Stockholders Equity is $0.0 Mil. Overall, Eagle Pharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Eagle Pharmaceuticals' Other Stockholders Equity compare to IXHL and RMTI?
Eagle Pharmaceuticals' Other Stockholders Equity of $0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Eagle Pharmaceuticals and its competitors. Eagle Pharmaceuticals's current Other Stockholders Equity is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eagle Pharmaceuticals stock overvalued right now?
Eagle Pharmaceuticals (EGRX) has a current Other Stockholders Equity of $0.0 Mil. The current Other Stockholders Equity is $0.0 Mil. Eagle Pharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Eagle Pharmaceuticals (EGRX), the current Other Stockholders Equity is $0.0 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eagle Pharmaceuticals Business Description

Address 50 Tice Boulevard, Suite 315, Woodcliff Lake, NJ, USA, 07677
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advance stages of development and is under review for approval by the Food and Drug Administration.
16GF Score

Get the complete analysis for EGRX

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.75
Price